Supplementary Figure 5 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

ERBB2 alterations were identified in the ctDNA of patients with metastatic urothelial cancer, indicating a distinct genomic profile.
Targeted sequencing unveiled significant findings, revealing critical insights into the molecular landscape of mUC.
The analysis of ctDNA offers a non-invasive approach to understanding tumor genetics, enhancing patient management insights.
These findings may enable future therapeutic strategies, calling for more comprehensive studies on ctDNA in urothelial cancer.

Targeted sequencing reveals ERBB2 alterations in circulating tumor DNA, suggesting potential biomarkers in metastatic urothelial cancer.

Supplementary Figure 5. Genomic landscape from targeted circulating tumor DNA (ctDNA) sequencing of ERBB2-altered metastatic urothelial cancer (mUC).

No takes yet. Share an insight, caveat, or question.

Vandekerkhove et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share